We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+2.35%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$7.71B
AUM Growth
-$201M
Cap. Flow
-$473M
Cap. Flow %
-6.14%
Top 10 Hldgs %
39.08%
Holding
169
New
28
Increased
15
Reduced
34
Closed
19

Top Buys

Rank Stock Value
1
NAUT icon
Nautilus Biotechnolgy
NAUT
+$96.5M
2
UTHR icon
United Therapeutics
UTHR
+$84.1M
3
OMIC
Singular Genomics Systems, Inc. Common Stock
OMIC
+$79.6M
4
ZY
Zymergen Inc. Common Stock
ZY
+$64.5M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$60M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$46.3M
2
ALLO icon
Allogene Therapeutics
ALLO
+$40.4M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$39.9M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$36.4M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$35.4M

Sector Composition

Rank Sector Weight
1 Healthcare 87.76%
2 Miscellaneous 11.22%
3 Financials 0.64%
4 Consumer Staples 0.2%
5 Industrials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RGNX icon
126
Regenxbio
RGNX
$525M
$3.47M 0.05%
89,283
+20,000
+29% +$715K
WGS icon
127
GeneDx Holdings
WGS
$2.82B
$3.18M 0.04%
6,879
+3,031
+79% +$1.3M
FULC icon
128
Fulcrum Therapeutics
FULC
$288M
$3.08M 0.04%
+294,118
New +$2.97M
SNCE
129
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$3M 0.04%
15,000
– –
GRTX
130
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$2.5M 0.03%
254,664
– –
KRRO icon
131
Korro Bio
KRRO
$207M
$2.21M 0.03%
4,444
-37,829
-89% -$18.5M
CEREW
132
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
$1.91M 0.02%
133,066
– –
MOTS
133
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$1.87M 0.02%
6,002
– –
SGTX
134
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
$1.34M 0.02%
9,615
– –
SRRA
135
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$1.3M 0.02%
66,655
– –
RACE icon
136
Ferrari
RACE
$71.5B
$1.28M 0.02%
6,200
– –
EIGR
137
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.19M 0.02%
4,663
– –
BFLY.WS
138
DELISTED
Butterfly Network Inc Warrants
BFLY.WS
$1.13M 0.01%
233,333
– –
SCPE.WS
139
DELISTED
SC Health Corporation Warrants, each whole warrant exercisable for one Class A ordinary share at an
SCPE.WS
$1.05M 0.01%
500,000
– –
PLXP
140
DELISTED
PLx Pharma Inc. Common Stock
PLXP
$793K 0.01%
57,459
-164,721
-74% -$1.95M
TKNO icon
141
Alpha Teknova
TKNO
$370M
$712K 0.01%
+30,000
New +$759K
TCRR
142
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$505K 0.01%
30,753
-282,547
-90% -$5.71M
PHVS icon
143
Pharvaris
PHVS
$2.67B
$503K 0.01%
27,000
– –
CMAXW
144
DELISTED
CareMax, Inc. Warrant
CMAXW
$283K ﹤0.01%
+60,000
New +$246K
RAPT
145
PUT
DELISTED
RAPT Therapeutics
RAPT
$83K ﹤0.01%
+5,625
New +$1.05M
ACAD icon
146
Acadia Pharmaceuticals
ACAD
$4.61B
– –
-1,410,305
Closed -$36.4M
ALLO icon
147
Allogene Therapeutics
ALLO
$594M
– –
-1,143,790
Closed -$40.4M
BIIB icon
148
CALL
Biogen
BIIB
$31.9B
– –
-748,000
Closed -$209M
BIIB icon
149
PUT
Biogen
BIIB
$31.9B
– –
-600,000
Closed -$168M
CMPS
150
Compass Pathways
CMPS
$1.91B
– –
-797,404
Closed -$29.4M
3 4 5
6
7

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q2 2021 Portfolio in Review

As of Q2 2021, Perceptive Advisors held 169 positions worth $7.71B, down 2.5% from $7.91B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Perceptive Advisors withdrew a net $473M in Q2 2021, closing 19 positions and reducing 34 holdings. Its most notable exit was Allogene Therapeutics, an estimated $40.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 84% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Perceptive Advisors opened a new position in Nautilus Biotechnolgy worth $90M.

  • Perceptive Advisors's largest Q2 2021 buy was Nautilus Biotechnolgy: 8,911,151 shares worth $90M.
  • Perceptive Advisors added most to United Therapeutics in Q2 2021, an estimated $84.1M increase.
  • Perceptive Advisors's biggest Q2 2021 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $46.3M.
  • Perceptive Advisors fully exited Allogene Therapeutics in Q2 2021, selling an estimated $40.4M.
  • Perceptive Advisors's ten largest holdings make up 39% of its $7.71B portfolio in Q2 2021.
  • Perceptive Advisors opened 28 new positions and closed 19 in Q2 2021.
  • Perceptive Advisors's portfolio value fell 2.5% quarter-over-quarter to $7.71B.

Based on Perceptive Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.